Cardiol Therapeutics Inc Class A Cash Flow Conversion Efficiency
Cardiol Therapeutics Inc Class A cash flow conversion efficiency. Based on the latest financial reports, Cardiol Therapeutics Inc Class A (CRDL) has a cash flow conversion efficiency ratio of -0.292x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$-5.23 Million ≈ $-3.78 Million USD) by net assets (CA$17.88 Million ≈ $12.93 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Cardiol Therapeutics Inc Class A (2017–2025)
Cash flow conversion efficiency of Cardiol Therapeutics Inc Class A from 2017 to 2025. This chart illustrates how Cardiol Therapeutics Inc Class A's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Cardiol Therapeutics Inc Class A share price for real-time trading data and today's change.
Cardiol Therapeutics Inc Class A Cash Flow Conversion Ratio Explained
Cardiol Therapeutics Inc Class A cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Cardiol Therapeutics Inc Class A Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cardiol Therapeutics Inc Class A ranked by their cash flow conversion efficiency. Also see CRDL stock market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Eastech Holding Limited
TW:5225
|
0.058x |
|
Mpact Limited
JSE:MPT
|
-0.008x |
|
Laxmi Goldorna House Ltd
NSE:LGHL
|
-0.023x |
|
Oncoclinicas do Brasil
SA:ONCO3
|
0.127x |
|
CLIO Cosmetics Co.Ltd
KQ:237880
|
0.015x |
|
Alarko Carrier Sanayi ve Ticaret AS
IS:ALCAR
|
-0.001x |
|
Tharimmune Inc.
NASDAQ:THAR
|
-0.016x |
|
Impiana Hotels Bhd
KLSE:7243
|
-0.111x |
Annual Cash Flow Conversion Efficiency for Cardiol Therapeutics Inc Class A (2017–2025)
The table below shows the annual cash flow conversion efficiency of Cardiol Therapeutics Inc Class A from 2017 to 2025. Review CRDL financial flexibility index to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CA$17.88 Million ≈ $12.93 Million |
CA$-23.85 Million ≈ $-17.26 Million |
-1.334x | -31.66% |
| 2024-12-31 | CA$24.73 Million ≈ $17.89 Million |
CA$-25.06 Million ≈ $-18.13 Million |
-1.013x | -13.68% |
| 2023-12-31 | CA$28.25 Million ≈ $20.43 Million |
CA$-25.18 Million ≈ $-18.22 Million |
-0.891x | -70.96% |
| 2022-12-31 | CA$52.20 Million ≈ $37.76 Million |
CA$-27.22 Million ≈ $-19.69 Million |
-0.521x | -68.80% |
| 2021-12-31 | CA$76.24 Million ≈ $55.15 Million |
CA$-23.55 Million ≈ $-17.04 Million |
-0.309x | +55.37% |
| 2020-12-31 | CA$13.27 Million ≈ $9.60 Million |
CA$-9.19 Million ≈ $-6.64 Million |
-0.692x | +10.76% |
| 2019-12-31 | CA$14.67 Million ≈ $10.61 Million |
CA$-11.38 Million ≈ $-8.23 Million |
-0.776x | -58.59% |
| 2018-12-31 | CA$22.27 Million ≈ $16.11 Million |
CA$-10.89 Million ≈ $-7.88 Million |
-0.489x | -8.02% |
| 2017-12-31 | CA$2.85 Million ≈ $2.06 Million |
CA$-1.29 Million ≈ $-934.75K |
-0.453x | -- |
About Cardiol Therapeutics Inc Class A
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for… Read more